Eli Lilly and Co said on Tuesday it plans to sell two versions of insulin products at half their current U.S. list prices, eight months after it started selling a half-priced version of its widely-used Humalog injection.
Not many investors had pegged the long-stagnant immunotherapy developer NantKwest as one of the big stock winners of this week. But on Monday, the first day of the J.P. Morgan Healthcare Conference, the stock soared 91% after the company’s founder and CEO, Dr. Patrick Soon-Shiong, gave an unusual television interview.
A initial hearing was scheduled for Wednesday in U.S. Bankruptcy Court for the Southern District of West Virginia on the Chapter 11 bankruptcy filing from Thomas Health System based in Kanawha County.
What a difference a year makes. The start of the annual J.P. Morgan Healthcare investor conference in 2019 brought a double-header of giant deals. In 2020, there was almost nothing. That wasn’t good news for biotech stocks. The iShares Nasdaq Biotech ETF ended Monday down 1.1% and the SPDR S&P Biotech ETF fell 2%.
Some people spend $200 a month on the golf course or on a fancy cable TV package, says David Westbrook, a hospital executive in Kansas City, Mo. His splurge? He pays Dr. John Dunlap $133 a month for what he considers exceptional primary care.
Biogen Inc said on Monday it has agreed to buy an early-stage experimental treatment from Pfizer Inc that it aims to test in patients with Alzheimer’s and Parkinson’s disease. Under the deal, Pfizer will get $75 million upfront and will be eligible for $635 million in potential milestone payments.